Campi Riccardo, Tellini Riccardo, Grosso Antonio Andrea, Pecoraro Alessio, Mari Andrea, Raspollini Maria Rosaria, Gacci Mauro, Carini Marco, Serni Sergio, Minervini Andrea
Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Eur Urol Open Sci. 2021 Oct 28;34:5-9. doi: 10.1016/j.euros.2021.09.009. eCollection 2021 Dec.
In response to the COVID-19 pandemic, the European Association of Urology (EAU) Guidelines Office Rapid Reaction Group (GORRG) defined priority groups to guide the prioritization of surgery for nonmetastatic renal cell carcinoma (RCC). In this study we explored the diversity and predictors of histopathological findings across the EAU GORRG priority groups using a large database of 1734 consecutive patients undergoing elective surgery for nonmetastatic renal masses between 2017 and 2020 at a referral institution. Overall, 940 (54.2%), 358 (20.6%), and 436 (25.2%) patients were classified as low-, intermediate-, and high-priority, respectively. The low-, intermediate-, and high-risk groups significantly differed regarding all primary histopathological outcomes: benign histology (21.6% vs 15.9% vs 6.4%; < 0.001); non-organ-confined disease (5.0% vs 19.0% vs 45.4%; < 0.001); and adverse pathological features according to validated prognostic models (including the median Leibovich score for clear-cell RCC: 0 vs 2 vs 4; < 0.001). On multivariable analysis, beyond the EAU GORRG priority groups, specific patient and/or tumor-related characteristics were independent predictors of the aforementioned histopathological outcomes. To the best of our knowledge, our study shows for the first time the value of the EAU GORRG priority groups from a histopathological standpoint and supports implementation of such a prioritization scheme beyond the COVID-19 pandemic.
During the COVID-19 pandemic, the European Association of Urology designed a scheme to prioritize patients needing surgery for kidney cancer according to their tumor characteristics and symptoms. We used results from our hospital database to test the scheme and found that the priority classification can be used to predict cancer outcomes after surgery. This scheme may be useful in prioritizing kidney cancer surgeries after the COVID-19 pandemic.
为应对新冠疫情,欧洲泌尿外科学会(EAU)指南办公室快速反应小组(GORRG)确定了优先治疗组,以指导非转移性肾细胞癌(RCC)手术的优先排序。在本研究中,我们使用了一个大型数据库,该数据库包含2017年至2020年期间在一家转诊机构接受非转移性肾肿块择期手术的1734例连续患者,探讨了EAU GORRG优先治疗组中组织病理学结果的多样性和预测因素。总体而言,分别有940例(54.2%)、358例(20.6%)和436例(25.2%)患者被归类为低、中、高优先级。低、中、高风险组在所有主要组织病理学结果方面存在显著差异:良性组织学(21.6%对15.9%对6.4%;<0.001);非器官局限性疾病(5.0%对19.0%对45.4%;<0.001);以及根据经过验证的预后模型得出的不良病理特征(包括透明细胞RCC的中位Leibovich评分:0对2对4;<0.001)。在多变量分析中,除了EAU GORRG优先治疗组外,特定的患者和/或肿瘤相关特征是上述组织病理学结果的独立预测因素。据我们所知,我们的研究首次从组织病理学角度显示了EAU GORRG优先治疗组的价值,并支持在新冠疫情之后实施这样的优先排序方案。
在新冠疫情期间,欧洲泌尿外科学会设计了一种方案来根据肾癌患者的肿瘤特征和症状对需要手术的患者进行优先排序。我们使用医院数据库的结果来测试该方案,发现优先分类可用于预测手术后的癌症结果。该方案可能有助于在新冠疫情之后对肾癌手术进行优先排序。